But the core RMD problem is not P/E or historic performance. It is future CPAP sale - and if GLP1 is about to take the market?
My view: GLP1 is an add on. CPAP is not going to get out of fashion all of a sudden. But some light OSA pt will get rid of their SX - and that is what bother SP.
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-172
-
- There are more pages in this discussion • 200 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$29.90 |
Change
1.250(4.36%) |
Mkt cap ! $18.94B | |||
| Open | High | Low | Value | Volume |
| $29.38 | $29.90 | $29.28 | $56.93M | 1.920M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2798 | $29.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $29.91 | 9379 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |